ArticleMolecular medicine (Cambridge, Mass.)2025
Rhein alleviates hepatic steatosis in NAFLD mice by activating the AMPK/ACC/SREBP1 pathway to enhance lipid metabolism.
Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Preclinical evaluation of puerarin for the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Sequential Fractionation ofFoods (Basel, Switzerland) · 2026Article
- A novel C/EBPα-miR-335-5p-PRKAA2 regulatory axis drives hepatic lipid accumulation in MASLD.Scientific reports · 2026Article
- Research on the Therapeutic Effect and Mechanism of Stir-Roasted Deer Velvet Antler with Ghee on Non-Alcoholic Fatty Liver Disease.Nutrients · 2026Article
- Mesenchymal Stromal/Stem Cell-Based Therapies for Liver Regeneration: Current Status and Future Directions.International journal of molecular sciences · 2026Review
- Rhein ameliorates MASH via EGFR/AKT/PPARα-mediated coordinated regulation of metabolism and inflammation.Frontiers in pharmacology · 2026Article
- Multi-target mechanisms and therapeutic potential of Dahuang Zhechong pill in lower extremity peripheral artery disease: a structured narrative review.Frontiers in pharmacology · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-alcoholic fatty liver disease (NAFLD) is a common metabolic liver disorder characterized by excessive lipid accumulation. The 5'-adenosine monophosphate-activated protein kinase (AMPK)/acetyl-CoA carboxylase (ACC)/sterol regulatory element-binding protein 1 (SREBP1) pathway plays a pivotal role in regulating lipid metabolism. Rhein, a natural compound, has demonstrated hepatoprotective potential; however, its mechanism of action in NAFLD remains unclear. This study aimed to investigate whether rhein ameliorates NAFLD through modulation of the AMPK/ACC/SREBP1 pathway.
methodsA murine NAFLD model was established using a high-fat diet (HFD). Mice were treated with varying doses of rhein, and their body weight, liver, kidney, and retroperitoneal fat weights were recorded. Liver pathology was assessed by histological examination and Oil Red O staining. Serum lipid profiles, liver function biomarkers, and inflammatory cytokine levels were measured. Western blotting was employed to analyze the expression and phosphorylation of AMPK pathway-related proteins (AMPK, ACC, and SREBP1). To validate the involvement of this pathway, AMPK-IN-3 was intraperitoneally administered in combination with high-dose rhein to a subset of HFD-fed mice.
resultsRhein treatment significantly reduced body weight gain, organ weights, hepatic lipid accumulation, serum cholesterol and triglyceride levels, and the expression of inflammatory cytokines in NAFLD mice. It also improved liver function markers, enhanced AMPK phosphorylation, promoted ACC phosphorylation, and inhibited SREBP1 expression. Notably, co-treatment with AMPK-IN-3 attenuated these beneficial effects, confirming the mechanistic involvement of the AMPK/ACC/SREBP1 pathway.
conclusionRhein confers protective effects against HFD-induced NAFLD by activating the AMPK/ACC/SREBP1 signaling pathway, thereby enhancing hepatic lipid metabolism, reducing steatosis, and alleviating liver injury and inflammation. These findings suggest that rhein may serve as a promising therapeutic candidate for NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.